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343* Effect of impaired glucose tolerance on clinical status in adult
CF patients
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Introduction: It has been suggested that impaired glucose tolerance (IGT) may be
associated with a decline in clinical status, as a precursor to frank diabetes mellitus
(CFRD). To look at this, we prospectively correlated glycaemic status with clinical
parameters in 60 consecutive adult CF patients not known to have CFRD.
Method: Using a standard oral glucose tolerance test (OGTT), we classiﬁed patients
as normal glucose tolerance (NGT), IGT, or CFRD, according to the 2-hour
glycaemic values (WHO criteria) and compared the results with clinical status,
including the need for IV therapy.
Results: Forty two (70%) had NGT, 10 (17%) IGT and 8 (13%) CFRD. There were
no signiﬁcant differences in age, sex, CFTR mutation, mean fasting plasma glucose
or microbial type/duration of infection between the 3 groups, correlation between
pancreatic enzyme supplementation and glycaemic status, and none had fasting
hyperglycaemia. Mean 2-hour OGTT glucose values were raised in patients with
IGT (mean±sem): 8.9±1.9 and CFRD 11.7±0.6, compared to NGT 5.3±1.4; both
p< 0.0001. BMI was similar between all groups (NGT 22.4±3.6, IGT 20.0±3.1,
DM 20.6±2.4; p = 0.15), but there was a trend towards poorer lung function in
the CFRD group (FEV1% predicted: NGT 65±24.3, IGT 64±17.9, DM 54±12.7;
p = 0.43). Similarly, CFRD patients had more hospital admissions in the preceding
year (3 v 1 per patient per year; p< 0.05).
Conclusions: This study shows that IGT was not associated with a decline in
nutritional status or pulmonary function, or predispose to pulmonary exacerbations
requiring hospital admission. From these data, it is difﬁcult to justify commencing
insulin therapy in these asymptomatic individuals, with the ensuing treatment burden
and impact on their quality of life.
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Background: Cystic ﬁbrosis-related diabetes (CFRD) is believed to be associated
with faster decline in pulmonary functions and with higher morbidity and mortality
in cystic ﬁbrosis (CF) patients. However, accurate matched patient control studies
are missing. We investigated retrospectively the decline in pulmonary functions
and BMI in patients with CFRD in comparison with matched CF patients without
diabetes.
Methods: 27 patients with insulin dependent CFRD and good diabetic management
(median HbA1c = 6.6) were matched with 27 CF patients without diabetes according
to gender, age, BMI, class of mutation, FEV1% predicted and infection status. Over
a period of 5 years the following parameters were studied: FEV1% predicted, FVC%
predicted, BMI and in-hospital days.
Results: At the start of this study, no differences between both patient groups
were seen. Over a period of 5 years, both groups showed a remarkable decline in
pulmonary functions. The rate of decline for FEV1% predicted was signiﬁcantly
higher in CFRD patients (2.2% decline/year vs. 1.4% decline/year, p = 0.049),
though this difference was not signiﬁcant for FVC% predicted. CFRD patients
tended to spend more days in hospital. BMI remained unchanged in both groups.
Conclusion: After 5 years, differences were found between CFRD patients and CF
patients without diabetes for FEV1 and in-hospital days, however not for FVC and
BMI. Unlike other studies, patients were properly matched and had good diabetic
control. This study shows that the clinical impact of CFRD is certainly present, but
probably smaller than originally presumed.
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Background: The association between Cystic Fibrosis Related Diabetes (CFRD),
deteriorating nutritional status, pulmonary health and worsening prognosis has
been demonstrated in numerous studies, mainly in adult patients. Quoted rates
for impaired glucose tolerance are 38% and 26% for CFRD in adolescents.
Methods: We performed an annual formal oral glucose tolerance test according
to the guidelines of the American Diabetes Association in 40 adolescent patients
(1.75g/kg of glucose, max. 75g). Patient age ranged from 9 to 16 years, the mean
age was 12.7 years, none of our patients was known to suffer from diabetes.
Results: We found the rates for impaired glucose tolerance and CFRD signiﬁcantly
lower than usually reported. 4 out of 40 patients (10%) had impaired glucose
tolerance, 1 out of 40 patients (2.5%) had CFRD. We found no signiﬁcant correlation
between 2 hour glucose levels and BMI, Shwachman scores, ﬁtness as assessed by
shuttle run distance or FEV1. Follow up data also showed no signiﬁcant correlation
for glucose levels and changes in BMI and FEV1.
Conclusion: In our group of adolescent patients we found the rates for glucose
intolerance lower than reported previously. Currently annual oral glucose tolerance
testing is the only valid screening tool for the detection of CFRD but it needs to be
repeated regularly as glucose intolerance does not correlate with other clinical data.
Further studies are necessary to establish the causative link between the aetiology
of CFRD and its clinical implications in CF patients.
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Low BMD is common in CF, yet there are few longitudinal studies of the
determinants of loss of bone mineral in adults with CF. This study aimed to measure
changes in BMD in CF adults over 3 years; and to identify clinical correlates of
loss of BMD.
Methods: Data were analysed from 47 adults with CF (55% male, mean age at base-
line 29.9±6.9 years) who had not received bisphosphonate or hormone replacement
therapy. Lumbar spine (LS) and femoral neck (FN) BMD and body composition
(lean tissue mass, LTM) were assessed using DXA scanning at baseline and follow-
up (mean 3.3±0.6 years later). Changes (DLSBMD, DFNBMD and DLTM) were
expressed as annual %change from baseline (ann%D). Clinical predictors (including
age, ann%DLTM, FEV1%predicted, corticosteroid use, calcium and vitamin D
supplements and serum 25-OH vitamin D levels) of ann%D in LS and FN BMD
were analysed using univariate analysis and multiple linear regression.
Results: 34% of patients lost >2% BMD per year at one or both sites. Baseline
BMD T-scores did not correlate with DBMD. Ann%DLTM was the only clinical
variable which correlated with ann%DLS BMD. This association was retained in
multivariate analysis (R2 = 0.21, p = 0.001). No variables correlated with ann%DFN
BMD. There were no atraumatic fractures during follow-up.
Conclusion: Loss of LTM was independently associated with loss of LS BMD, sug-
gesting that declining nutritional status is a risk factor for developing osteoporosis.
This highlights the importance of identifying and treating loss of LTM in CF.
LS BMD
(g/cm2)
LS T-score FN BMD
(g/cm2)
FN T-score LTM (kg) FEV1pred.
Baseline 1.147±0.125 −0.57±1.00 1.014±0.131 −0.14±1.06 46.7±8.7 67.4±21.4
Annual %change 0.01±1.40 n/a −1.50±1.45* n/a 0.1±1.0 −1.0±2.6*
Data show mean±SD. *p< 0.01.
